WHO says investment in new R&D tools can eradicate malaria
The World Health Organization (WHO) has claimed that malaria can be eradicated with accelerated research...
Read More...
Focus:
Global
-
![GLP-1RA undergoes change]()
Another GLP-1 receptor agonist win for Novo Nordisk
Despite the increasing competition, Novo Nordisk has been able to protect its dominance in the...
Read More...
-
![Crohn's disease benchmarking]()
Crohn’s disease Phase II mAb benchmarking
Benchmarking Crohn’s disease in Phase II mAbs trials using GlobalData’s Feasibility Planner can give those...
Read More...
-
![Most popular gene therapies]()
Top gene therapy drugs 2014–2018
In recent years, there have been several promising clinical trial results within the therapeutic field...
Read More...
-
![Biologics investment 2019]()
Investor interest in biologics continues: Three hefty $100m+ biologic IPOs in May alone
Biologics companies are increasingly coming to market with their pipelines at an earlier stage of...
Read More...
-
![Antimicrobial resistance 2019]()
WHO tool sets its sights on tackling antimicrobial resistance
Antimicrobial resistance (AMR), which threatens to claim 10 million lives a year by 2050, is widely regarded as one of…
Read More…
-
![Gene therapy for neurological disorders]()
What are the looming gene therapies for central nervous system indications?
According to GlobalData’s Pharma Intelligence Center, 14 CNS indications are the subjects of gene therapy-based...
Read More...
-
![Big pharma pollution]()
Landmark study shows pharma worse than the automotive industry for carbon emissions
In addition to the lack of awareness of pharma’s contribution to climate change, lack of...
Read More...
-
![Ovarian cancer treatment]()
Long-awaited novel therapies for ovarian cancer have arrived
GlobalData anticipates that the clinical development efforts to diversify available therapies in ovarian cancer will...
Read More...
-
![]()
Pain pipeline characterised by innovative programmes in early-stage development
Opioids, which are the cornerstone of moderate-to-severe pain management, account for a sizable 40% of...
Read More...
